RxDoctor Payments Data

Lindsey Porta, MD

Family Medicine · Brookville, INNPI 1669811253

Payments from drug & device makers

$1,660in general payments, 2019–2025

Across 96 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$289
  • Novo Nordisk$275
  • Pfizer$235
  • Axsome Therapeutics, Inc.$171
  • AstraZeneca$146
  • Radius Health, Inc.$83
  • plus $462 from 10 others

What the payments were for

  • Food & beverage$1,62798%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,660 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$70,429
Medicare patients
196
Services billed
1,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$74,917
JardianceEmpagliflozin31$29,588
EliquisApixaban28$26,908
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$21,386
TrulicityDulaglutide23$20,950
FarxigaDapagliflozin Propanediol15$15,484
MounjaroTirzepatide14$13,971
MyrbetriqMirabegron13$8,689
Breo ElliptaFluticasone/Vilanterol18$6,855
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,340
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen121$1,657
Diclofenac Sodium24$875
Omeprazole73$842
Atorvastatin Calcium116$809
Ventolin HfaAlbuterol Sulfate14$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$275$74,91755 claims
Lilly USA, LLCTrulicity, Mounjaro$15$34,92037 claims
Boehringer IngelheimJardiance$67$29,58831 claims
GSKTrelegy Ellipta, Breo Ellipta$29$28,24151 claims
PfizerEliquis$235$26,90828 claims
AstraZenecaFarxiga$146$15,48415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Brookville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →